Image caption Caroline Wyatt visited Prof Robin Franklin to find out more about a drug that might help stop the progression of MS
"I don't like to think of the future. It's such a big question mark. I just keep living in the present."
Karine Mather was diagnosed with MS when she was 27, although she noticed the first symptoms much earlier.
It started off as a mental-health issue with anxiety and depression, she remembers. Later, she noticed she was starting to limp when she walked longer distances.
Karine began using a walker to help with her balance and stamina, and then a scooter when she could no longer walk very far.
"I got to the stage where the wheelchair became quite liberating, and gave me back a sense of freedom again. Now I rely on the power-chair full-time because I can't stand by myself any more."
Now Karine and her wife, Sarah, have had to give up their full-time jobs.
Karine was forced to stop working as a customer service adviser at a bank because she could no longer fulfil the physical demands of work and Sarah gave up working as a data analyst so she could take care of Karine.
Now 34, Karine retains the use of just one hand, and suffers pain, stiffness and spasticity in her body that has got worse as the disease has progressed.
"It feels like a fist clenching all the time. And I have days when my mind is cloudy and I miss out words and sentences."
Both remain upbeat but the financial, as well as the emotional, impact of MS has been huge.
Karine's MS is the type known as "primary progressive", or PPMS, which meant that for the first years after diagnosis, no disease-modifying treatment was available.
One new drug - Ocrevus, or ocrelizumab - was recently licensed for early PPMS in the UK but came too late to help Karine.
Now the MS Society is launching an ambitious "Stop MS" appeal, aiming to raise 100m to fund research over the next decade into treatments that can stop the progression of disability in MS.
Since being diagnosed with MS in 2015, after many years of symptoms, I've been looking for anything that might help slow or even stop the progression of my MS, which affects the nerves in my brain and spinal cord.
I last wrote about my MS after travelling to Mexico for an autologous stem cell transplant (aHSCT) in 2017.
Sadly, despite initial improvements, I'm now back to where I was before: slowly but surely getting worse.
The only improvements that have endured are the lifting of some of the crushing brain fog I had before HSCT and less hesitation in my speech.
For both, I am eternally grateful, as they mean I can continue to work at the BBC, in the job I love.
However, I have no idea how long this reprieve will last.
The fatigue that had long been my worst symptom is now back with a vengeance, so that staying awake throughout a busy working day remains a challenge.
That MS fatigue did lift for a few months, and it felt miraculous. I awoke every day refreshed. But then it returned, and I awake after eight full hours fast asleep feeling as if I haven't been to bed at all.
The ageing process - including menopause - has almost certainly been a factor in the worsening of some symptoms.
Ageing cells repair less well, and with my faulty immune system apparently determined to keep stripping away the myelin sheath that should protect my nerves, I'm less able now to repair the damage than I was when the disease first began to affect me in around 1992.
Since 2016, I've had to walk using a stick to aid my balance. It is sparkly-topped; an effort to make the accoutrements of disability just a little more cheery.
Dizziness is now a constant companion. It rarely goes away, making car travel or even buses a nightmare. Just turning my head too fast can make me stagger or fall over.
And for the past year or two, my right foot has begun to drag along the ground thanks to foot drop, meaning that I trip more often because I can't fully raise it.
I am always grateful to the strangers who kindly stop to help me up from the uneven pavement when I do fall.
Perhaps most worrying for me is that my right hand no longer works as it used to, catching on the computer keyboard as my outer fingers drag lazily along the keys, sullenly refusing my brain's command to lift.
In the mornings, both my hands and my feet are numb and frozen, then painfully full of pins and needles before warming up enough to be usable a few hours later.
When I wake, I wonder how long it might be until these hands and feet barely function at all, and quickly push that unwelcome thought away.
I'm well aware how very lucky I am that the progression of my MS has been relatively slow - at least until recently. I've learned how better to conserve energy for the things that really matter, though I still chafe at how little I manage to achieve.
Having enough energy to cook a meal from scratch on a day off is a cause for rejoicing. I'm still learning how to save up enough energy for family and friends, and not use up all of my much-depleted ration for work or research.
I have had to face the fact that I have now probably gone from the relapsing-remitting phase of MS (for which a dozen or so treatments exist) into the secondary progressive phase, for which there is currently no treatment licensed in the UK to stop the relentless progression that will affect so many of the 100,000 or more of us living with MS here.
But that may be about to change.
Anna Williams, professor of regenerative neurology at the University of Edinburgh, is looking at how the brain responds to MS damage and how the fatty myelin sheath under attack in MS can be restored more efficiently.
"We have to look at ways to stop the nerves dying," she says. "We want to be able to try to limit that either by keeping the nerves alive, or keeping them working better."
Repurposing existing drugs to help with remyelination should prove the quickest route to therapies for progressive forms of MS, because creating and licensing new ones is a much lengthier and more expensive process.
Prof Williams still sees patients at the Anne Rowling Clinic of Regenerative Neurology in Edinburgh, named in memory of the Harry Potter author J K Rowling's mother, who had MS. (The author this year donated 15m for research at the unit.)
"At the moment, with PPMS or SPMS, we can always give relief for pain or stiffness but we won't change the course of the disease.
"So for those patients, to slow or stop or reverse the disease can only be done with more research, and money is critical for research."
The biggest trial yet in the UK for patients with secondary progressive MS is the MS STAT2 trial, conducted by Prof Jeremy Chataway for the UCL Queen Square Institute of Neurology in London.
The trial is still recruiting at 30 centres across the UK to look at whether simvastatin, a drug used to treat high cholesterol, can slow or stop disability progression. If so, it has the potential to become one of the first disease-modifying therapies for people with secondary progressive MS.
And perhaps most encouraging of all, Prof Robin Franklin and his team at the Wellcome-MRC Cambridge Stem Cell Institute recently published research suggesting a common diabetes drug - metformin - could hold the key to stopping disease progression in MS.
Costing just a few pence per tablet, metformin appears to have an ability to restore cells to a younger, healthier state and encourage myelin regrowth.
The next question is whether it works in people as well as it does in the lab.
Prof Franklin says: "This is a drug that's well tolerated and widely available. There is every reason to believe that the effects that we have seen - which have been so spectacular - will translate into humans.
"This is the great frontier of MS therapy. We're good at stopping the inflammation in MS. What we're not so good at doing is repairing the damage. All this work has given us some real hope that this medicine will reverse the damage done by MS."
I certainly feel rather more hopeful than I did.
I've changed as much about my lifestyle as I can - prioritising sleep, eating healthily, largely giving up alcohol, doing yoga and stretching every day, and cutting back on stress, be that reporting from war zones or attending too many BBC meetings.
But I'm all too aware that time is against me as my ageing brain and body struggle to repair the damage done in their lengthy continuing battle with my own immune system.
My hope now is that these trials will show good enough results in the next few years for at least one or two of the drugs to be rapidly approved for MS so they can help people like Karine and me before it's too late.
I ask Karine what she makes of the current research.
She is suitably succinct.
"I'm sitting here with just the one limb working and I'm thinking - quicker, please."
Read the original here:
Caroline Wyatt: The fight to reverse damage caused by MS - BBC News
- Mapping out the mystery of blood stem cells - Science Codex - November 26th, 2020
- Scientists Reveal a New Drug That Directs Stem Cells To Desired Sites - Science Times - November 26th, 2020
- Celularity Announces Dosing of First Patient in Phase I Study of Human Placental Hematopoietic Stem Cell-Derived Natural Killer Cells (CYNK-001) in... - November 26th, 2020
- The stem/progenitor landscape is reshaped in a mouse model of essential thrombocythemia and causes excess megakaryocyte production - Science Advances - November 26th, 2020
- Novartis bags Mesoblast's stem cell therapy for ARDS, including in Covid-19, in a deal worth up to $1.2B+ - Endpoints News - November 24th, 2020
- Global Stem Cells Market is estimated to account for US$ 18289.9 Mn by end of 2027, Says Coherent Market Insights (CMI) - Business Wire - November 24th, 2020
- Adherence to Allogeneic Stem Cell Transplantation to Improve Survival in Myelodysplastic Syndromes - Hematology Advisor - November 24th, 2020
- Anakinra: efficacy in the management of fever during neutropenia and mucositis in autologous stem cell transplantation (AFFECT-2)-study protocol for a... - November 24th, 2020
- Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing... - November 24th, 2020
- CAR T-cell therapy treatment helps cancer patient beat near impossible odds - ABC News - November 24th, 2020
- Correlation of whole-bone marrow dual-time-point (18)F-FDG, as measured by a CT-based method of PET/CT quantification, with response to treatment in... - November 24th, 2020
- Late Effects of Therapy Plague Many Patients Who Survived AML as Youths, Young Adults - AJMC.com Managed Markets Network - November 24th, 2020
- Rescue Therapy with Bendamustine and Other Agents May Result in High Response Rates in Relapsed or Refractory NHL - Curetoday.com - November 24th, 2020
- Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman - BioSpace - November 24th, 2020
- Exploring First-line Therapies in Peripheral T-Cell Lymphomas - Targeted Oncology - November 24th, 2020
- Israeli Scientists Discover Oxygen Beauty Treatment That Can Make You Look 25 Years Younger - All You Need to - India.com - November 24th, 2020
- Novartis licenses phase 3 COVID-19 cell therapy from Mesoblast - FierceBiotech - November 22nd, 2020
- Benefits of Hematopoietic Stem Cell Transplantation in Advanced Myelodysplastic Syndromes - Hematology Advisor - November 22nd, 2020
- YOUR HEALTH: Your body may already have the answer to knee pain - WQAD.com - November 22nd, 2020
- Providing CAR T-Cell Therapy for Patients With DLBCL During COVID-19 - Targeted Oncology - November 22nd, 2020
- BioRestorative Therapies Emerges from Chapter 11 Reorganization - OrthoSpineNews - November 22nd, 2020
- Stem Cell Therapy Market 2020 Trends, Market Share, Industry Size, Growth, Sales, Opportunities, Analysis and Forecast To 2026 - The Daily... - November 22nd, 2020
- Animal Stem Cell Therapy Market 2020 Impact of COVID-19 | Size, Share & Latest Trends, Analysis Report by Manufacturers, Application, Type and... - November 22nd, 2020
- Canine Stem Cell Therapy Market 2020 impact of COVID-19 on Industry Size, Share, Global Analysis, Development Status, Regional Trends, Opportunity... - November 22nd, 2020
- Stem Cell Therapy Market, Share, Application Analysis, Regional Outlook, Competitive Strategies & Forecast up to 2026 - The Daily Philadelphian - November 22nd, 2020
- gift of life marrow registry announces new center for cell and gene therapy - The Boca Raton Tribune - November 22nd, 2020
- Global Canine Stem Cell Therapy Industry Market Analysis, Key Company Profiles, Types, Applications and Forecast To 2026 - Royal Sutton News - November 22nd, 2020
- Increasing Progenitor Cell Proliferation in the Sub-Ventricular Zone: A Therapeutic Treatment for Progressive Multiple Sclerosis? - DocWire News - November 22nd, 2020
- Glycostem initiates phase I/IIa (pivotal) trial to evaluate the safety and efficacy of oNKord in patients with Acute Myeloid Leukemia (AML) -... - November 22nd, 2020
- Impact Analysis of Covid-19 On Global Stem Cell Therapy Market Continues to Expand to Support Development and Top Players: Magellan, Medipost Co.,... - November 22nd, 2020
- Adrenoleukodystrophy Treatment Market: Rising awareness about rare diseases to drive the market - BioSpace - November 22nd, 2020
- AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - The Baytown Sun - November 16th, 2020
- Mesenchymal stem cells in the treatment of COVID-19-progress and challenges - DocWire News - November 16th, 2020
- The Animal Stem Cell Therapy market to fill the growth bill in the next decade - The Think Curiouser - November 16th, 2020
- Malaysia Animal Stem Cell Therapy Market Size 2020 | Opportunities, Regional Overview, Top Leaders, Revenue and Forecast to 2027 - Eurowire - November 16th, 2020
- Addenbrooke's becomes first regional centre to offer CAR-T cell treatment for cancer patients - Cambridge Network - November 16th, 2020
- Stem Cell Therapy Market 2020 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2025 - The Daily Philadelphian - November 16th, 2020
- Mesenchymal stem cells in therapy of coronavirus disease 2019 - a review - DocWire News - November 16th, 2020
- Global cryotherapy market size to reach USD 6.72 billion by 2026 - GlobeNewswire - November 16th, 2020
- Stem Cell Therapy Market 2020 Future Growth Factors and Opportunities by 2025 - PRnews Leader - November 16th, 2020
- Stem Cell Therapy Market 2020 Trends, Growth Insight, Share, Competitive Analysis, Statistics, Regional and Global Industry Forecast To 2025 - PRnews... - November 16th, 2020
- BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for... - November 16th, 2020
- Stem Cell Banking Market To See Massive Growth By 2027| Cryo-Save AG, StemCyte India Therapeutics, SMART CELLS PLUS, Vita 34, LifeCell - PRnews Leader - November 9th, 2020
- It's time for Kentucky to talk to expectant parents about benefits of cord blood banking - Courier Journal - November 9th, 2020
- Global Stem Cell Therapy Market 2020 : Analysis of Expansion Strategy on Industry, Growth Factors and Expected CAGR Of Top Leaders, Upcoming... - November 9th, 2020
- Stem Cell Banking Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2028|Esperite, Caladrius Biosciences, Via Cord, CBR... - November 9th, 2020
- Doctors Consider Convalescent T Cell Therapy for COVID-19 - The Scientist - November 7th, 2020
- Canine Stem Cell Therapy Market Analysis, Latest Trends and Regional Growth Forecast by Types and Applications 2020 - TechnoWeekly - November 7th, 2020
- Cancer Stem Cell Therapy Market: Industry Trends and Developments 2020-2025 - Zenit News - November 7th, 2020
- Stem Cell Therapy Market 2020: Size, Professional Survey, and Forecast to 2025 - PRnews Leader - November 7th, 2020
- The Adipose Tissue Derived Stem Cells market to grow in the wake of incorporation of the latest technology - The Think Curiouser - November 7th, 2020
- Novel Targeted Drugs are Changing the Treatment of Diffuse Large B-Cell Lymphoma - Curetoday.com - November 7th, 2020
- Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease - GlobeNewswire - November 7th, 2020
- Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American... - November 7th, 2020
- bluebird bio to Present Data from Gene and Cell Therapy Programs During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition -... - November 7th, 2020
- Voters approve stem cell research bonds, but other health care measures defeated - State of Reform - State of Reform - November 5th, 2020
- Stem cells key to ALS therapy - Agoura Hills Acorn - November 5th, 2020
- Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling. - UroToday - November 5th, 2020
- New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation - DocWire News - November 5th, 2020
- Emerging Trends in Global Canine Stem Cell Therapy Market Report 2020,Deeply Analyzes Share, Types, Applications and Future Demands by Key Players-... - November 5th, 2020
- Dr. Braunschweig on Selecting Between Transplant and CAR T-Cell Therapy in DLBCL - OncLive - November 5th, 2020
- Canine Stem Cell Therapy Market Size, Share Analysis by Manufacturers, Regions, Type and Application to 2026 - PRnews Leader - November 5th, 2020
- Stem Cell Therapy Market Insights Global Analysis and Forecast by (2020 2027) - The Think Curiouser - November 5th, 2020
- Animal Stem Cell Therapy Consumption Market To Observe Exponential Growth By 2020-2027 | Verified Market Research - Eurowire - November 5th, 2020
- Orchard Therapeutics' gene therapy Strimvelis linked to a leukemia case - FiercePharma - November 5th, 2020
- Stem Cell Therapy Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or Loose out From the Impact of... - November 5th, 2020
- Animal Stem Cell Therapy Market Future Demand Analysis with Forecast 2020 to 2027 - PRnews Leader - November 5th, 2020
- Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX... - November 5th, 2020
- Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of... - November 5th, 2020
- CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology... - November 5th, 2020
- Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting - Business Wire - November 5th, 2020
- XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy in multiple myeloma - BioSpace - November 5th, 2020
- Global Autologous Cell Therapy Market will Showcase Neutral Impact During 2020-2024 | Use of Biomass as a Fuel in Boiler to Boost Market Growth |... - November 5th, 2020
- Animal Stem Cell Therapy Market Size 2020-2026 Review, Key Findings, Growth Strategy, Developing Technologies, Trends And Global Forecast By Regions -... - November 5th, 2020
- Covid-19 Impact On Animal Stem Cell Therapy Market Analysis, Trends, Share, Size, Consumption 2020 2026 | MediVet Biologic, VETSTEM BIOPHARMA, J-ARM,... - November 5th, 2020
- Stem Cell Therapy for Autism: Effects & Costs in 2020 - November 1st, 2020
- aHSCT Gets a Boost in US With NMSS Recommendations - Multiple Sclerosis News Today - November 1st, 2020
- Optimal Health: Cutting Edge Restorative Treatments Cityview - Knoxville City View - November 1st, 2020
- How pain changes your brain - News - The University of Sydney - November 1st, 2020
- Could an Imaging Test Predict How Well Youll Respond to a Stem Cell Transplant? - SurvivorNet - October 31st, 2020
